Introducing Nemluvio: Atopic Dermatitis and Prurigo Nodularis Treatment Nemluvio (nemolizumab) has recently received FDA approval for managing atopic dermatitis and prurigo nodularis. What Is Nemluvio? Nemluvio is targets the IL-31 receptor alpha, a key player in the skin’s inflammatory response and the sensation of itching. By interrupting this pathway, Nemluvio effectively reduces inflammation, itch, and… Read More
